DUBLIN--(BUSINESS WIRE)--The 'Rare Kidney Diseases Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Disease Indications, Type of Molecule, Type of Biologics, Route of Administration, Type of Therapy, Key Geographical Regions, Leading Drug Developers and Sales Forecast' report has been added to ResearchAndMarkets.com's offering..

都柏林--（商业新闻短讯）--“罕见肾脏疾病市场：行业趋势和全球预测，到2035年：按目标疾病适应症、分子类型、生物制剂类型、给药途径、治疗类型、关键地理区域、领先药物开发商和销售预测的分布”报告已添加到ResearchAndMarkets.com的产品中。。

The global rare kidney diseases market is estimated to grow from $3.9 billion in 2024 to $12.1 billion by 2035, representing a CAGR of 11%, during the forecast period 2024-2035.

据估计，全球罕见肾脏疾病市场将从2024年的39亿美元增长到2035年的121亿美元，在2024-2035年的预测期间，复合年增长率为11%。

This research study consists of industry trends, detailed rare kidney diseases market analysis, key market insights, partnerships and collaborations analysis, funding and investments, clinical trial analysis and market impact analysis. The report includes rare diseases market forecast and opportunity analysis..

这项研究包括行业趋势、详细的罕见肾脏疾病市场分析、关键市场见解、合作伙伴关系和合作分析、资金和投资、临床试验分析和市场影响分析。该报告包括罕见病市场预测和机会分析。。

Rare kidney diseases are a group of conditions, with at least 150 different disorders falling into this category. In Europe, a rare kidney disease is defined as rare when the prevalence is less than 1 in 2000 people and in the US, the disease is designated rare when less than 200,000 people are affected.

罕见的肾脏疾病是一组疾病，至少有150种不同的疾病属于这一类。在欧洲，当患病率低于2000人中的1人时，罕见肾脏疾病被定义为罕见；在美国，当患病率低于200000人时，该疾病被指定为罕见。

It is worth mentioning that in 2020, of more than 8,000 individuals diagnosed with rare kidney disease, only 500 received treatment for a rare kidney disease received treatment. Studies have also shown that 12% individuals with kidney failure suffer from a rare kidney disease leading to chronic debilitation and morbidity.

值得一提的是，2020年，在8000多名被诊断患有罕见肾脏疾病的人中，只有500人接受了罕见肾脏疾病的治疗。。

Thereby, several initiatives have been taken by stakeholders to promote the development of therapeutics focused on rare kidney diseases..

因此，利益相关者采取了多项举措，以促进针对罕见肾脏疾病的治疗方法的发展。。

It is worth mentioning that, since 2019, around USD 8 billion has been invested in companies developing therapies for rare kidney diseases. However, advancements in the diagnosis and treatment of rare kidney diseases have been hampered by several factors, including limited patient population, lack of prognostic biomarkers, clinical heterogeneity, and insufficient model organisms.

值得一提的是，自2019年以来，约有80亿美元投资于开发罕见肾脏疾病治疗方法的公司。然而，罕见肾脏疾病的诊断和治疗进展受到多种因素的阻碍，包括患者人数有限，缺乏预后生物标志物，临床异质性和模式生物不足。

To address such challenges, several promising advancements have been made in this domain..

为了应对这些挑战，在这一领域取得了一些有希望的进展。。

For instance, the emergence of precision medicine (genomic sequencing and personalized therapies) has enabled the targeted treatment of rare kidney diseases, drug repurposing involving the identification of new therapeutic targets and leveraging the pharmacological properties for existing drugs which has emerged as a cost-effective strategy for treating rare kidney diseases.

例如，精准医学（基因组测序和个性化治疗）的出现使罕见肾脏疾病的靶向治疗成为可能，药物重新利用涉及确定新的治疗靶点，并利用现有药物的药理学特性，这已成为治疗罕见肾疾病的一种具有成本效益的策略。

It is worth mentioning that the integration of artificial intelligence (AI) and machine learning algorithms to optimize the personalized treatment of rare kidney diseases is one of the prominent examples of technological advancements in the rare kidney diseases market..

。。

Over the past few years, a number of rare kidney disease drugs targeting a myriad of indications have received approval from various regulatory authorities, globally. In 2023, the Food and Drug Administration (FDA) granted approval for Elfabrio (developed by Protalix BioTherapeutics) for the treatment of Fabry Disease.

。2023年，美国食品和药物管理局（FDA）批准Elfabrio（由Protalix BioTherapeutics开发）用于治疗法布里病。

Additionally, the FDA granted approval to Tarpeyo (developed by Calliditas Therapeutics) for the treatment of IgA Nephropathy. Given the lucrative opportunity associated with these drugs, the rare kidney diseases market has gained attention of both private and public investors in the past few years leading to the substantial market growth during the forecast period..

此外，FDA批准Tarpeyo（由Calliditas Therapeutics开发）用于治疗IgA肾病。鉴于与这些药物相关的利润丰厚的机会，罕见肾脏疾病市场在过去几年中受到了私人和公共投资者的关注，导致预测期内市场大幅增长。。

Rare Kidney Diseases Market Key Insights

罕见肾脏疾病市场关键见解

The report features an extensive study of the current market landscape, market size and future opportunities associated with developers within the rare kidney disease, during the given forecast period. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of rare kidney diseases industry.

该报告对给定预测期内罕见肾病开发商的当前市场格局、市场规模和未来机会进行了广泛研究。市场报告强调了几个利益相关者在罕见肾脏疾病行业这一迅速崛起的领域所做的努力。

Key takeaways of the rare kidney diseases market report are briefly discussed below..

下面简要讨论罕见肾脏疾病市场报告的主要要点。。

Competitive Landscape of Drug Developers for Rare Kidney Diseases

罕见肾脏疾病药物开发人员的竞争格局

The current market landscape features the presence of over 115 companies involved in developing various rare kidney disease therapies. In addition, more than 20 rare kidney disease drugs have been commercialized for targeting various indications with more than 115 therapies in the clinical stage of development.

目前的市场格局是有超过115家公司参与开发各种罕见肾脏疾病疗法。此外，20多种罕见肾脏疾病药物已商业化，用于针对各种适应症，在临床开发阶段有超过115种疗法。

Furthermore, the rare kidney disease market features the presence of small, mid-sized and large companies having the required expertise to develop and commercialize therapies..

此外，罕见肾脏疾病市场的特点是存在具有开发和商业化治疗所需专业知识的中小型和大型公司。。

Rare Kidney Diseases Market Trends: Increasing Partnerships and Collaborations to Foster Progress and Innovation

罕见肾脏疾病市场趋势：增加伙伴关系和合作以促进进步和创新

The rare kidney disease drug developers have forged several partnerships with other stakeholders in order to enhance their drug portfolios. The growing need for rare kidney disease therapies is evident from the rise in partnership activity in the rare kidney disease market. It is worth highlighting that a significant increase has been witnessed in 2023, wherein majority of the deals were focused on product and technology licensing, followed by the instances of stakeholders collaborating for research and development.

罕见肾脏疾病药物开发人员与其他利益相关者建立了一些合作伙伴关系，以增强其药物组合。罕见肾脏疾病市场合作活动的增加表明，对罕见肾脏疾病疗法的需求日益增长。值得强调的是，2023年出现了大幅增长，其中大多数交易都集中在产品和技术许可上，其次是利益相关者合作研发的情况。

In November 2023, Cabaletta Bio entered into a technology licensing agreement with Cellares to manufacture CABA-201, for treating Lupus Nephritis. This can be attributed to the incessant efforts of stakeholders to further advance the development of their drugs across different phases of preclinical and clinical development.

2023年11月，Cabaletta Bio与Celles签订了技术许可协议，生产用于治疗狼疮性肾炎的CABA-201。这可以归因于利益相关者不断努力，在临床前和临床开发的不同阶段进一步推进其药物的开发。

Such partnerships are expected to drive significant rare kidney diseases market growth during the forecast period..

预计这种合作关系将在预测期内推动罕见肾脏疾病市场的大幅增长。。

Key Drivers of the Rare Kidney Diseases Market

罕见肾脏疾病市场的主要驱动力

The funding raised, government initiatives and the likely future potential of rare kidney disease therapies will primarily drive the rare kidney diseases market. It is interesting to note that over the past few years, development efforts in rare kidney diseases domain have been adequately supported by various government and non-government agencies.

筹集的资金、政府举措以及罕见肾脏疾病治疗的未来潜力将主要推动罕见肾脏疾病市场。值得注意的是，在过去几年中，各种政府和非政府机构充分支持了罕见肾脏疾病领域的发展努力。

Venture capital firms and other key investors have invested around USD 8 billion in the last 5 years in the companies working towards development of therapeutics targeting rare kidney diseases..

风险投资公司和其他主要投资者在过去5年中向致力于开发针对罕见肾脏疾病的治疗药物的公司投资了约80亿美元。。

Also, the increasing awareness and understanding of rare kidney diseases have strengthened this domain with several events being conducted by stakeholders. For instance, in September 2023, the American Kidney Fund (AKF) conducted a general awareness campaign for C3 Glomerulopathy and IgA Nephropathy, which was sponsored by Novartis.

此外，随着利益相关者开展的多项活动，人们对罕见肾脏疾病的认识和理解不断提高，这一领域得到了加强。。

Such initiatives will increase the awareness amongst the public, improve the diagnosis and treatment rates, driving the rare kidney disease market..

这些举措将提高公众的认识，提高诊断和治疗率，推动罕见肾脏疾病市场。。

Rare Kidney Diseases Market Size: Drugs Targeting Fabry Disease Hold the Largest Market Share

The global market opportunity for rare kidney diseases is estimated to be more than $3.9 billion in 2024 which is anticipated to grow at CAGR of 11% during the forecast period 2024-2035. The market growth is primarily fueled by increasing incidence of Fabry diseases, encouraging the stakeholders to develop drugs with higher efficacy rates..

。市场增长主要是由于法布里病发病率的增加，鼓励利益相关者开发疗效更高的药物。。

North America Holds the Largest Share of the Rare Kidney Diseases Market

北美拥有罕见肾脏疾病市场的最大份额

In 2024, North America is anticipated to capture close to 50% market share of the overall rare kidney diseases market. In recent years, research activity for rare kidney diseases has witnessed a tremendous increase in North America. Further, it is worth highlighting that, market in Asia-Pacific is likely to grow at a CAGR of 8.5% during the forecast period 2024-2035..

预计2024年，北美将占据整个罕见肾脏疾病市场近50%的市场份额。近年来，北美对罕见肾脏疾病的研究活动急剧增加。此外，值得强调的是，在2024-2035年的预测期内，亚太地区的市场可能以8.5%的复合年增长率增长。。

Leading Drug Developers in the Rare Kidney Diseases Market

罕见肾脏疾病市场的领先药物开发商

Examples of key developers involved in the rare kidney diseases industry (which have also been captured in this market report, arranged in alphabetical order) include Alexion Pharmaceuticals, Chinook Therapeutics, Horizon Therapeutics, Jiangsu Hengrui Pharmaceuticals, Novartis, Omeros, Roche, Sanofi, Travere Therapeutics, ZyVersa Therapeutics, Advicenne, Apellis Pharmaceuticals, argenx, Astellas Pharma, Boehringer Ingelheim, Calliditas Therapeutics, GSK, Mallinckrodt Pharmaceuticals, Synlogic and Takeda.

参与罕见肾脏疾病行业的关键开发商的例子（本市场报告也按字母顺序排列）包括亚力兄制药，奇努克治疗，地平线治疗，江苏恒瑞制药，诺华，奥梅罗斯，罗氏，赛诺菲，特拉维尔治疗，ZyVersa治疗，Advicenne，Apellis制药，argenx，Astellas制药，勃林格殷格翰，Calliditas治疗，GSK，Mallincrodt制药，Synlogic和武田。

This market report includes an easily searchable excel database of all the developers involved in the development of rare kidney diseases therapies..

这份市场报告包括一个易于搜索的excel数据库，其中包含参与罕见肾脏疾病疗法开发的所有开发人员。。

Key Attributes:

关键属性：

Report Attribute

报表属性

Details

详细信息

No. of Pages

页数

240

240

Forecast Period

预测期

2024 - 2035

2024 - 2035

Estimated Market Value (USD) in 2024

2024年估计市值（美元）

$3.9 Billion

39亿美元

Forecasted Market Value (USD) by 2035

2035年预测市场价值（美元）

$12.1 Billion

121亿美元

Compound Annual Growth Rate

年均复合增长率

11.0%

11.0%

Regions Covered

覆盖的区域

Global

Rare Kidney Diseases Market Share Insights

罕见肾脏疾病市场份额洞察

The market research report presents an in-depth analysis of the various rare kidney disease developers that are involved in the global rare kidney diseases industry, across different segments, as defined below:

市场研究报告深入分析了全球罕见肾脏疾病行业中涉及不同细分市场的各种罕见肾脏疾病开发商，定义如下：

Historical Trend: 2018-2023

历史趋势：2018-2023

Base Year: 2024

基准年：2024年

Forecast Period: 2024-2035

预测期：2024-2035年

Market Size Value in 2024: $3.9 Billion

2024年市场规模价值：39亿美元

Growth Rate: CAGR of 11% from 2024 to 2035

增长率：2024年至2035年复合年增长率为11%

Type of Target Disease Indication

目标疾病适应症类型

Atypical Hemolytic Uremic Syndrome

非典型溶血尿毒症综合征

Fabry Disease

法布里病

Immunoglobulin A Nephropathy

免疫球蛋白A肾病

Focal Segmental Glomerulosclerosis

局灶节段性肾小球硬化

Autosomal Dominant Polycystic Kidney Disease

常染色体显性遗传性多囊肾病

Lupus Nephritis

狼疮性肾炎

Others

其他

Type of Molecule

分子类型

Small Molecules

小分子

Biologics

生物制剂

Type of Biologic

生物制剂类型

Monoclonal Antibodies

单克隆抗体

Proteins

蛋白质

Route of Administration

给药途径

Oral

口头

Intravenous

静脉注射

Subcutaneous

皮下

Others

其他

Type of Therapy

治疗类型

Monotherapy

单一疗法

Combination Therapy

联合治疗

Leading Drug Developers

领先的药物开发商

Alexion Pharmaceuticals

亚力兄制药

Amicus Therapeutics

Amicus治疗学

Aurinia Pharmaceuticals

Aurinia制药公司

GSK

GSK

Otsuka Pharmaceutical

大冢制药

Mallinckrodt Pharmaceuticals

马林克罗特制药公司

Novartis

诺华公司

Otsuka Pharmaceutical

大冢制药

Roche

罗氏公司

Sanofi

赛诺菲

Travere Therapeutics

Travere疗法

Other Players

其他玩家

Leading Market Players

领先的市场参与者

Alexion Pharmaceuticals

亚力兄制药

Chinook Therapeutics

Horizon Therapeutics

地平线疗法

Jiangsu Hengrui Pharmaceuticals

江苏恒瑞制药

Novartis

诺华公司

Omeros

奥梅罗斯

Roche

罗氏公司

Sanofi

赛诺菲

Travere Therapeutics

Travere疗法

ZyVersa Therapeutics

ZyVersa治疗学

Advicenne

Advicenne公司

Apellis Pharmaceuticals

Apellis制药公司

argenx

argenx

Astellas Pharma

阿斯特拉制药

Boehringer Ingelheim

勃林格殷格翰

Calliditas Therapeutics

卡利迪斯疗法

GSK

GSK

Mallinckrodt Pharmaceuticals

马林克罗特制药公司

Synlogic

Synlogic

Takeda

塔克达

Excel Data Packs (Complimentary)

Excel数据包（免费）

Market Landscape Analysis

市场前景分析

Company Competitiveness Analysis

公司竞争力分析

Partnerships and Collaborations

伙伴关系和合作

Funding and Investments

资金和投资

Clinical Trial Analysis

临床试验分析

Clinical Commercial Attractiveness

Key Opinion Leaders

关键意见领袖

Market Size and Opportunity Analysis

市场规模和机会分析

For more information about this report visit https://www.researchandmarkets.com/r/axp25v

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/axp25v

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。